Craig-Hallum initiated coverage of Neurogene (NGNE) with a Buy rating and $50 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene Approves Amendments at Annual Stockholders Meeting
- Neurogene price target raised to $26 from $22 at BMO Capital
- Neurogene Highlights Gene Therapy Advancements in New Update
- Neurogene Reports Q1 2025 Financial Progress and Updates
- Optimistic Buy Rating for Neurogene Amid Favorable Market and Regulatory Conditions